Steven Cohen’s Point72 Asset Management disclosed a 5.2% stake in Design Therapeutics (DSGN), which represents over 2.94M shares. The filing with the SEC does not allow for activism.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DSGN:
- Design Therapeutics Reports Increased R&D Expenses Amid Net Loss
- Design Therapeutics: Hold Rating Amid Regulatory Hurdles and Financial Caution
- Design Therapeutics Advances GeneTAC Programs Amid FDA Hold
- Design Therapeutics reports Q2 EPS (34c), consensus (33c)
- Design Therapeutics Faces Financial Strain Amid International Trade Challenges